Amplimmune seeks to identify partners to collaborate with and to develop novel immunological products in the oncology, autoimmune, infectious disease, and/or transplantation settings.

See Amplimmune Corporate Summary

Current Partnering Opportunities:

AMP-110 for the treatment of 1) autoimmune/inflammatory disorders and 2) transplantation.

See AMP-110 Program Overview

The company also is investigating other new potential product candidates in the above-mentioned fields that are available for R&D partnerships.

To inquire about partnership opportunities at Amplimmune, please email: businessdevelopment@amplimmune.com

Current Partners:



In August of 2010, Amplimmune entered into a broad strategic alliance with GlaxoSmithKline (GSK) to further develop PD-1 targeting therapies that may be effective in the treatment of cancer and other diseases. GSK and Amplimmune will develop AMP-224 as well as other potential next generation fusion proteins that target PD-1.